Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.94
$0.172.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -21.57% | -14.97% | |||
| Gross Profit | 31.99% | 7.29% | |||
| SG&A Expenses | -3.09% | 3.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.88% | -10.89% | |||
| Operating Income | 22.68% | 4.71% | |||
| Income Before Tax | 30.72% | -5.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.72% | -5.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.72% | -5.01% | |||
| EBIT | 22.68% | 4.71% | |||
| EBITDA | 23.14% | 4.75% | |||
| EPS Basic | 30.82% | -4.91% | |||
| Normalized Basic EPS | 24.95% | 3.30% | |||
| EPS Diluted | 30.82% | -4.91% | |||
| Normalized Diluted EPS | 24.95% | 3.30% | |||
| Average Basic Shares Outstanding | 0.14% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||